| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2022: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2021: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2020: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study was to overcome the interstitial barrier that prevents drug delivery and to establish a new radioimmunotherapy strategy that is effective against intractable solid tumors. Cancer stroma-targeting antibodies were highly accumulated in a solid tumor model with abundant cancer stroma. The antibody labeled with beta-emitting nuclide Y-90 showed a promising treatment for pancreatic cancer alone. Furthermore, when a release-type ADC was used in combination, an even higher therapeutic effect was obtained. A characteristic pathological image was observed in the combination group. It is considered that the cell cycle was arrested in the mitotic phase due to the influence of the anticancer drug used for ADC. It is assumed that this effect was responsible for the radiation sensitization effect. Our therapeutic strategy has shown promise for the treatment of refractory solid tumors.
|
